
|Articles|December 5, 2012
NDA accepted for kidney cancer agent
AVEO Oncology and Astellas Pharma Inc. have announced that the FDA has accepted for filing the new drug application (NDA) for tivozanib with the proposed indication for the treatment of patients with advanced renal cell carcinoma.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Sean P. Collins, MD, PhD, outlines the impact of rectal spacers for men with prostate cancer
2
ORIC-944 shows promise in combination with ARPIs for mCRPC
3
Jason Hafron, MD, recaps prostate cancer data from ESMO 2025
4
Community practice experience shows early efficacy, favorable safety with nadofaragene
5




















